This article is more than 5 years old. Information may no longer be current.

Sirion receives NDA acceptance and priority review for topical ocular inflammation treatment

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

TAMPA, Fla. — Sirion Therapeutics' new drug application for a potential new topical ocular anti-inflammatory drug has been accepted by the U.S. Food and Drug Administration and granted priority review, the company announced in a press release.

Sirion is seeking FDA approval for Durezol (0.05% difluprednate ophthalmic emulsion), a twice-daily topical steroid being developed for treating ocular inflammatory diseases, including postoperative ocular inflammation, the release said.